272 related articles for article (PubMed ID: 23102868)
1. The treatment of visceral leishmaniasis (kala-azar) in India: no obvious signs of long-term success.
Muniaraj M; Paramasivan R; Mariappan T; Arunachalam N; Sinha PK
Trans R Soc Trop Med Hyg; 2012 Dec; 106(12):770-2. PubMed ID: 23102868
[TBL] [Abstract][Full Text] [Related]
2. Sodium stibogluconate-sensitive visceral leishmaniasis in the non-endemic hilly region of Uttarakhand, India.
Verma SK; Ahmad S; Shirazi N; Kusum A; Kaushik RM; Barthwal SP
Trans R Soc Trop Med Hyg; 2007 Jul; 101(7):730-2. PubMed ID: 17382981
[TBL] [Abstract][Full Text] [Related]
3. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.
Sundar S; More DK; Singh MK; Singh VP; Sharma S; Makharia A; Kumar PC; Murray HW
Clin Infect Dis; 2000 Oct; 31(4):1104-7. PubMed ID: 11049798
[TBL] [Abstract][Full Text] [Related]
4. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.
Thakur CP; Narayan S; Ranjan A
Indian J Med Res; 2004 Sep; 120(3):166-72. PubMed ID: 15489554
[TBL] [Abstract][Full Text] [Related]
5. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
[TBL] [Abstract][Full Text] [Related]
6. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
[TBL] [Abstract][Full Text] [Related]
7. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.
Rijal S; Chappuis F; Singh R; Bovier PA; Acharya P; Karki BM; Das ML; Desjeux P; Loutan L; Koirala S
Trans R Soc Trop Med Hyg; 2003; 97(3):350-4. PubMed ID: 15228258
[TBL] [Abstract][Full Text] [Related]
8. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India.
Thakur CP; Dedet JP; Narain S; Pratlong F
Trans R Soc Trop Med Hyg; 2001; 95(2):187-9. PubMed ID: 11355558
[TBL] [Abstract][Full Text] [Related]
9. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
[TBL] [Abstract][Full Text] [Related]
10. Ketoconazole in antimonial unresponsive cases of Kala-azar.
Jha TK; Singh NK; Jha S
J Assoc Physicians India; 1995 May; 43(5):347. PubMed ID: 9081966
[No Abstract] [Full Text] [Related]
11. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
12. Treatment of kala-azar in India.
Thakur CP
Natl Med J India; 1992; 5(5):203-5. PubMed ID: 1338871
[No Abstract] [Full Text] [Related]
13. Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.
Thakur CP; Thakur S; Narayan S; Sinha A
Indian J Med Res; 2008 Jun; 127(6):582-8. PubMed ID: 18765878
[TBL] [Abstract][Full Text] [Related]
14. Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study.
Perry MR; Prajapati VK; Menten J; Raab A; Feldmann J; Chakraborti D; Sundar S; Fairlamb AH; Boelaert M; Picado A
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003518. PubMed ID: 25730310
[TBL] [Abstract][Full Text] [Related]
15. Sodium antimony resistant cases of kala-azar in and around Patna (south Bihar).
Sehgal PN; Murmu C; Chatteyee AK
J Commun Dis; 1988 Jun; 20(2):161-2. PubMed ID: 2853714
[No Abstract] [Full Text] [Related]
16. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.
Lira R; Sundar S; Makharia A; Kenney R; Gam A; Saraiva E; Sacks D
J Infect Dis; 1999 Aug; 180(2):564-7. PubMed ID: 10395884
[TBL] [Abstract][Full Text] [Related]
17. Drug unresponsiveness & combination therapy for kala-azar.
Jha TK
Indian J Med Res; 2006 Mar; 123(3):389-98. PubMed ID: 16778318
[TBL] [Abstract][Full Text] [Related]
18. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.
Thakur CP; Sinha GP; Pandey AK; Kumar N; Kumar P; Hassan SM; Narain S; Roy RK
Ann Trop Med Parasitol; 1998 Jul; 92(5):561-9. PubMed ID: 9797829
[TBL] [Abstract][Full Text] [Related]
19. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
Singh N; Chatterjee M; Sundar S
Parasit Vectors; 2014 Dec; 7():596. PubMed ID: 25515494
[TBL] [Abstract][Full Text] [Related]
20. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
Dube A; Singh N; Sundar S; Singh N
Parasitol Res; 2005 Jun; 96(4):216-23. PubMed ID: 15868188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
